;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Aldoxorubicin: Phase Ib started

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 9/15/2014
  • ALKS 7106: Phase I started

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 7106 Business: Neurology Molecular target: NA Description: Oral small molecule opioid analgesic Indication: Treat pain Endpoint: Safety and pharmacokinetics …

    Published on 9/15/2014
  • AVP-786: Phase II started

    Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: AVP-786, CTP-786 (formerly deuterated dextromethorphan) Business: Neurology Molecular …

    Published on 9/15/2014
  • BL-8040: Phase I started

    Biokine Therapeutics Ltd., Tel Aviv, Israel BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Product: BL-8040 (formerly BKT-140) Business: Hematology Molecular target: CXC chemokine receptor 4 (CXCR4) (…

    Published on 9/15/2014
  • CB-5083: Phase I started

    Cleave Biosciences Inc., Burlingame, Calif. Product: CB-5083 Business: Cancer Molecular target: Valosin containing protein (VCP) (p97) Description: A highly selective valosin containing protein (VCP; p97) inhibitor …

    Published on 9/15/2014
  • CureXcell: Completed Phase III enrollment

    Macrocure Ltd. (NASDAQ:MCUR), Petah Tikva, Israel Product: CureXcell Business: Dermatology Molecular target: NA Description: Suspension containing activated allogeneic white blood cells isolated from the peripheral …

    Published on 9/15/2014
  • DiaPep277: Development discontinued

    Evotec AG (Xetra:EVT), Hamburg, Germany Hyperion Therapeutics Inc. (NASDAQ:HPTX), South San Francisco, Calif. Product: DiaPep277 Business: Endocrine/Metabolic Molecular target: NA Description: Peptide composed of 24 …

    Published on 9/15/2014
  • Emricasan: Phase II started

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), San Diego, Calif. Product: Emricasan (PF-3491390, IDN-6556, PF-03491390) Business: Hepatic Molecular target: Caspases Description: Pan-caspase inhibitor Indication: Treat …

    Published on 9/15/2014
  • Emricasan: Phase II started

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), San Diego, Calif. Product: Emricasan (PF-3491390, IDN-6556, PF-03491390) Business: Hepatic Molecular target: Caspases Description: Pan-caspase inhibitor Indication: Treat …

    Published on 9/15/2014
  • FF-10501: Phase I/IIa started

    Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan Product: FF-10501 Business: Cancer Molecular target: NA Description: Inhibitor of hematological cancer cell growth Indication: Treat advanced hematologic malignancies …

    Published on 9/15/2014
  • KHK7580: Phase IIb started

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: KHK7580 Business: Endocrine/Metabolic Molecular target: NA Description: Calcium receptor agonist …

    Published on 9/15/2014
  • KVD001: Phase I started

    KalVista Pharmaceuticals Ltd., Southampton, U.K. Product: KVD001 Business: Ophthalmic Molecular target: NA Description: Intravitreal plasma kallikrein inhibitor Indication: Treat diabetic macular edema (DME) Endpoint: …

    Published on 9/15/2014
  • LJPC-501: Phase I/II started

    La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Product: LJPC-501 Business: Hepatic Molecular target: NA Description: Renin-angiotensin system peptide agonist Indication: Treat hepatorenal syndrome (HRS) …

    Published on 9/15/2014
  • Metadoxine ER: Phase IIb started

    Alcobra Ltd. (NASDAQ:ADHD), Tel Aviv, Israel Product: Metadoxine ER (MDX) (MG01CI) Business: Neurology Molecular target: Serotonin (5-HT2B) receptor Description: Extended-release formulation of metadoxine, a selective …

    Published on 9/15/2014
  • MGCD516: Phase I started

    Mirati Therapeutics Inc. (NASDAQ:MRTX), San Diego, Calif. Product: MGCD516 (formerly MG516) Business: Cancer Molecular target: c-Met proto-oncogene (MET) (HGFR); Ret proto-oncogene (RET) Description: Second-generation, …

    Published on 9/15/2014
  • Oxycyte: Phase IIb halted

    Oxygen Biotherapeutics Inc. (NASDAQ:OXBT), Morrisville, N.C. Product: Oxycyte Business: Inflammation Molecular target: Not applicable Description: Perfluorocarbon-based IV therapeutic oxygen carrier Indication: Treat …

    Published on 9/15/2014
  • Palbociclib: Expanded access program started

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Palbociclib (PD-0332991) Business: Cancer Molecular target: Cyclin dependent kinase 4 (CDK4); Cyclin dependent kinase 6 (…

    Published on 9/15/2014
  • Pracinostat: Completed Phase II enrollment

    MEI Pharma Inc. (NASDAQ:MEIP), San Diego, Calif. Product: Pracinostat (formerly SB939) Business: Cancer Molecular target: Histone deacetylase (HDAC) Description: Class I, II and IV oral histone deacetylase (HDAC) …

    Published on 9/15/2014
  • Reolysin: Completed Phase II enrollment

    Andrus Reo Ltd., Moscow, Russia Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY), Calgary, Alberta Product: Reolysin Business: Cancer Molecular target: Not applicable Description: Formulation of human reovirus type 3 …

    Published on 9/15/2014
  • Rhopressa: Phase III started

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: Rhopressa (AR-13324) Business: Ophthalmic Molecular target: Rho kinase; Norepinephrine transporter Description: Dual inhibitor of Rho kinase and the …

    Published on 9/15/2014
  • Secnidazole: Completed Phase II enrollment

    Symbiomix Therapeutics LLC, Newark, N.J. Product: Secnidazole (SYM-1219) Business: Infectious Molecular target: NA Description: 5-nitroimidazole antibiotic Indication: Treat bacterial vaginosis Endpoint: Number of …

    Published on 9/15/2014
  • SNS01-T: Completed Phase Ib/IIa enrollment

    Sevion Therapeutics Inc. (OTCQB:SNTI), Bridgewater, N.J. Product: SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01, a compound …

    Published on 9/15/2014
  • ThermoDox heat-activated liposome: Phase III started

    Celsion Corp. (NASDAQ:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd. (Tokyo:2267), Tokyo, Japan Zhejiang Hisun Pharmaceutical Co. Ltd. (Shanghai:600267), Taizhou City, China Product: ThermoDox heat-activated liposome…

    Published on 9/15/2014
  • Translarna ataluren: Completed Phase III enrollment

    PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Product: Translarna ataluren (formerly PTC124) Business: Musculoskeletal Molecular target: Not available Description: Small molecule that facilitates complete …

    Published on 9/15/2014
  • WF10: Completed Phase II enrollment

    Nuvo Research Inc. (TSX:NRI), Mississauga, Ontario Product: WF10 (formerly OXO-K993) Business: Inflammation Molecular target: Not available Description: Tetrachlorodecaoxygen chlorite matrix Indication: Treat refractory…

    Published on 9/15/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993